Drugs / RPh201
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT01513967 | Jan 2012 → Jun 2015 | — | Regenera Pharma Ltd | Completed | No outcome recorded |
| Phase 1/2 | NCT01429519 | Dec 2011 → Dec 2012 | chronic ulcer of skin | Regenera Pharma Ltd | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT01455480 | Dec 2011 | — | Regenera Pharma Ltd | Withdrawn | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT03547206 | Jul 2018 → Sep 2020 | non-arteritic anterior ischemic optic neuropathy | Regenera Pharma Ltd | Terminated | No outcome recorded |
| Phase 2 | NCT03462121 | Mar 2018 → Dec 2019 | Alzheimer disease, cerebrovascular disorder | Regenera Pharma Ltd | Completed | No outcome recorded |
| Phase 2 | NCT02045212 | Feb 2014 → Aug 2016 | non-arteritic anterior ischemic optic neuropathy | Regenera Pharma Ltd | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01438684 Comparator | Sep 2012 → Jan 2019 | akinetic mutism | Hadassah Medical Organization | Suspended | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RPh201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01513967 ↗ |
| Route | Topical | “administered topically three times per week” NCT01429519 ↗ |